MetaCap

Agios Pharmaceuticals Inc. (AGIO)

NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

27.60-1.16 (-4.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AGIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$6.31
52-week range
24.16 – 44.09
Day range
27.43 – 29.14
Volume / Avg
776.16K / 1.06M
Beta
—

52-week range

$24.16$44.09

AGIO stock today

Shares of Agios Pharmaceuticals (AGIO) finished lower on Nov 20 at $27.60, a drop of 4.03% or $1.16 per share, versus the S&P 500's 3.70% decline. At this level, AGIO sits near the bottom of its 52-week range of $24.16 to $44.09: 37.4% below the high, set on Jul 7, 2026 and 14.2% above the low. AGIO is up 1.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.4%.

Agios Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$6.31), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Agios Pharmaceuticals

Company profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Brian M. Goff M.B.A.
Headquarters
Cambridge, MA
Employees
539
IPO year
2013
Website
agios.com

Financial highlights

Full financials

In fiscal 2025, Agios Pharmaceuticals generated $54.0 million in revenue, up 48.0% from fiscal 2024, its 4th consecutive year of revenue growth. Agios Pharmaceuticals reported a net loss of $412.8 million, compared with net income of $673.7 million a year earlier. Gross margin was 88.3% (down from 88.6%) and operating margin -873.9%.

Agios Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$54.03M$36.50M$26.82M$14.24M$0
Growth+48.03%+36.07%+88.36%——
Net income$-412.78M$673.73M$-352.09M$-231.80M$1.60B
EPS (diluted)$-7.12$11.64$-6.33$-4.23$26.55

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$46.11+67.07%

  • Strong buy 0
  • Buy 7
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $32.00High $74.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.09 vs $-1.32
Surprise
+17.42%

AGIO news

All AGIO news

Agios Pharmaceuticals peers

Health Care sector
AGIO peer companies
CompanyPrice% ChgMarket capCompare
BRVEBraveheart Bio Inc.20.39+5.81%$1.67Bvs AGIO
RAREUltragenyx Pharmaceutical Inc.16.48-4.30%$1.68Bvs AGIO
ZBIOZenas BioPharma Inc.23.85-4.75%$1.62Bvs AGIO
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs AGIO
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs AGIO
ANIPANI Pharmaceuticals Inc.68.55-0.84%$1.56Bvs AGIO
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs AGIO
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs AGIO

Indexes, lists and sector

Agios Pharmaceuticals stock FAQ

What is Agios Pharmaceuticals's stock price today?

AGIO last traded at $27.60 as of Nov 20, 4:00 PM EST, down 4.03% on the day. Prices are delayed at least 15 minutes.

Who is Agios Pharmaceuticals's CEO?

Mr. Brian M. Goff M.B.A. is the chief executive officer of Agios Pharmaceuticals Inc., which has about 539 employees.

What is the AGIO 52-week high?

The 52-week high for AGIO is $44.09 and the 52-week low is $24.16. The stock is currently 37.4% below its high.

Compare AGIO